Article info
PDFResearch ethics
Paper
Defining categories of actionability for secondary findings in next-generation sequencing
- Correspondence to Professor Samia A Hurst, Institute for Ethics History and the Humanities, Geneva University Medical School, 1 rue Michel Servet, Geneva 1211, Switzerland; samia.hurst{at}unige.ch
Citation
Defining categories of actionability for secondary findings in next-generation sequencing
Publication history
- Received May 10, 2016
- Revised September 13, 2016
- Accepted December 9, 2016
- First published December 30, 2016.
Online issue publication
April 25, 2017
Article Versions
- Previous version (25 April 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort
- Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification
- Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases
- Comprehensive genetic sequence and copy number analysis for Charcot-Marie-Tooth disease in a Canadian cohort of 2517 patients
- Detection of copy number variants associated with late-onset conditions in ~16 200 pregnancies: parameters for disclosure and pregnancy outcome
- Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort
- Prospective analysis of 895 patients on a UK Genomics Review Board
- De novo recurrent germline mutation of theBRCA2 gene in a patient with early onset breast cancer
- Variants of Uncertain Significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling
- Clinical application of fetal genome-wide sequencing during pregnancy: position statement of the Canadian College of Medical Geneticists